Reata initiates phase II/III study of bardoxolone methyl to treat Alport syndrome-associated CKD Feb. 24, 2017
Revive Therapeutics and InMed in term sheet agreement for cannabinoid therapies for kidney diseases Feb. 23, 2017
RSS